Payment overview · 2025
General Payments
$315.96
17 reported records · 9 companies
Healthcare provider profile · identity verified
John Gregory Elders, MD
Allopathic & Osteopathic Physicians|Family Medicine · MOUNTAIN HOME, AR · NPI 1174520688
Verified facts
What the public records show
CMS Open Payments records show John Gregory Elders, MD received $315.96 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $128.38 | 40.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.83 | 12.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.71 | 12.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.00 | 6.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.94 | 6.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.63 | 5.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.07 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.89 | 4.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.51 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $315.96 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $82.96 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $82.96 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $60.67 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.42 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 183 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
183 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 695 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 82 |
| Metformin Hcl | Metformin Hcl | 299 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 299 | 87 |
| Gabapentin | Gabapentin | 295 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 256 | 65 |
| Lisinopril | Lisinopril | 250 | 61 |
| Losartan Potassium | Losartan Potassium | 248 | 63 |
| Omeprazole | Omeprazole | 228 | 55 |
| Alprazolam | Alprazolam | 212 | 32 |
| Furosemide | Furosemide | 205 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 200 | 58 |
| Famotidine | Famotidine | 199 | 67 |
| Tramadol Hcl | Tramadol Hcl | 199 | 54 |
| Potassium Chloride | Potassium Chloride | 190 | 58 |
| Eliquis | Apixaban | 183 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 173 | 35 |
| Sertraline Hcl | Sertraline Hcl | 157 | 31 |
| Prednisone | Prednisone | 145 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 131 | 43 |
| Allopurinol | Allopurinol | 129 | 31 |
| Simvastatin | Simvastatin | 124 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 41 |
| Donepezil Hcl | Donepezil Hcl | 115 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 23 |
| Meloxicam | Meloxicam | 101 | 28 |
| Carvedilol | Carvedilol | 97 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 18 |
| Lovastatin | Lovastatin | 89 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 25 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 83 | 83 |
| Glimepiride | Glimepiride | 83 | 17 |
| Trazodone Hcl | Trazodone Hcl | 80 | 23 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 73 | 55 |
| Warfarin Sodium | Warfarin Sodium | 73 | 13 |
| Finasteride | Finasteride | 70 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 20 |
| Alendronate Sodium | Alendronate Sodium | 63 | 17 |
| Buspirone Hcl | Buspirone Hcl | 63 | 17 |
| Atenolol | Atenolol | 53 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 15 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 50 | 11 |
| Cefdinir | Cefdinir | 49 | 38 |
| Mirtazapine | Mirtazapine | 49 | 15 |
| Bumetanide | Bumetanide | 48 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Irbesartan | Irbesartan | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | 11 |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Metformin Hcl Er | Metformin Hcl | 41 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 35 | 35 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 17 |
| Spironolactone | Spironolactone | 35 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 13 |
| Klor-Con 10 | Potassium Chloride | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | 12 |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 17 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $315.96 · 17 records | PFIZER INC. | ABRYSVO, AIRSUPRA, Auvelity, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE, FREESTYLE LIBRE 3, GARDASIL 9, MOUNJARO, NURTEC ODT, PENBRAYA, PREVNAR 20, QULIPTA, TRUMENBA, UBRELVY, VAXNEUVANCE, VRAYLAR, YUPELRI, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error